Literature DB >> 35652333

Fibrinogen and Factor XIII in Venous Thrombosis and Thrombus Stability.

Alisa S Wolberg1, Yaqiu Sang1.   

Abstract

As the third most common vascular disease, venous thromboembolism is associated with significant mortality and morbidity. Pathogenesis underlying venous thrombosis is still not fully understood. Accumulating data suggest fibrin network structure and factor XIII-mediated crosslinking are major determinants of venous thrombus mass, composition, and stability. Understanding the cellular and molecular mechanisms mediating fibrin(ogen) and factor XIII production and function and their ability to influence venous thrombosis and resolution may inspire new anticoagulant strategies that target these proteins to reduce or prevent venous thrombosis in certain at-risk patients. This article summarizes fibrinogen and factor XIII biology and current knowledge of their function during venous thromboembolism.

Entities:  

Keywords:  anticoagulant; fibrinogen; hemostasis; red blood cell; venous thrombosis

Mesh:

Substances:

Year:  2022        PMID: 35652333      PMCID: PMC9339521          DOI: 10.1161/ATVBAHA.122.317164

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   10.514


  145 in total

Review 1.  Factor XIII: novel structural and functional aspects.

Authors:  I Komáromi; Z Bagoly; L Muszbek
Journal:  J Thromb Haemost       Date:  2011-01       Impact factor: 5.824

Review 2.  Fibrinogen, red blood cells, and factor XIII in venous thrombosis.

Authors:  B L Walton; J R Byrnes; A S Wolberg
Journal:  J Thromb Haemost       Date:  2015-06       Impact factor: 5.824

Review 3.  Inhibitors of blood coagulation factor XIII.

Authors:  Thomas Schmitz; Charlotte A Bäuml; Diana Imhof
Journal:  Anal Biochem       Date:  2020-04-23       Impact factor: 3.365

4.  Transformation of cellular factor XIII into an active zymogen transglutaminase in thrombin-stimulated platelets.

Authors:  L Muszbek; G Haramura; J Polgár
Journal:  Thromb Haemost       Date:  1995-04       Impact factor: 5.249

5.  Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions.

Authors:  P W Kamphuisen; J C Eikenboom; H L Vos; R Pablo; A Sturk; R M Bertina; F R Rosendaal
Journal:  Thromb Haemost       Date:  1999-05       Impact factor: 5.249

6.  Minimal factor XIII activity level to prevent major spontaneous bleeds.

Authors:  M Menegatti; R Palla; M Boscarino; P Bucciarelli; L Muszbek; E Katona; M Makris; F Peyvandi
Journal:  J Thromb Haemost       Date:  2017-08-17       Impact factor: 5.824

7.  Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders.

Authors:  F Peyvandi; R Palla; M Menegatti; S M Siboni; S Halimeh; B Faeser; H Pergantou; H Platokouki; P Giangrande; K Peerlinck; T Celkan; N Ozdemir; C Bidlingmaier; J Ingerslev; M Giansily-Blaizot; J F Schved; R Gilmore; A Gadisseur; M Benedik-Dolničar; L Kitanovski; D Mikovic; K M Musallam; F R Rosendaal
Journal:  J Thromb Haemost       Date:  2012-04       Impact factor: 5.824

8.  Fibrinogen β chain and FXIII polymorphisms affect fibrin clot properties in acute pulmonary embolism.

Authors:  Adrianna Klajmon; Jakub Chmiel; Michał Ząbczyk; Elżbieta Pociask; Ewa Wypasek; Krzysztof P Malinowski; Anetta Undas; Joanna Natorska
Journal:  Eur J Clin Invest       Date:  2021-11-21       Impact factor: 4.686

Review 9.  Disorders of Fibrinogen and Fibrinolysis.

Authors:  Jori E May; Alisa S Wolberg; Ming Yeong Lim
Journal:  Hematol Oncol Clin North Am       Date:  2021-08-14       Impact factor: 2.861

10.  Platelet vinculin: a substrate of activated factor XIII.

Authors:  G M Asijee; L Muszbek; J Kappelmayer; J Polgár; A Horváth; A Sturk
Journal:  Biochim Biophys Acta       Date:  1988-06-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.